Titre : Villes

Villes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Villes : Questions médicales les plus fréquentes", "headline": "Villes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Villes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Villes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régions géographiques", "url": "https://questionsmedicales.fr/mesh/D005842", "about": { "@type": "MedicalCondition", "name": "Régions géographiques", "code": { "@type": "MedicalCode", "code": "D005842", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Baltimore", "alternateName": "Baltimore", "url": "https://questionsmedicales.fr/mesh/D015142", "about": { "@type": "MedicalCondition", "name": "Baltimore", "code": { "@type": "MedicalCode", "code": "D015142", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.100" } } }, { "@type": "MedicalWebPage", "name": "Pékin", "alternateName": "Beijing", "url": "https://questionsmedicales.fr/mesh/D000068476", "about": { "@type": "MedicalCondition", "name": "Pékin", "code": { "@type": "MedicalCode", "code": "D000068476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.114" } } }, { "@type": "MedicalWebPage", "name": "Boston", "alternateName": "Boston", "url": "https://questionsmedicales.fr/mesh/D001900", "about": { "@type": "MedicalCondition", "name": "Boston", "code": { "@type": "MedicalCode", "code": "D001900", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.210" } } }, { "@type": "MedicalWebPage", "name": "Chicago", "alternateName": "Chicago", "url": "https://questionsmedicales.fr/mesh/D002641", "about": { "@type": "MedicalCondition", "name": "Chicago", "code": { "@type": "MedicalCode", "code": "D002641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.305" } } }, { "@type": "MedicalWebPage", "name": "District de Columbia", "alternateName": "District of Columbia", "url": "https://questionsmedicales.fr/mesh/D004219", "about": { "@type": "MedicalCondition", "name": "District de Columbia", "code": { "@type": "MedicalCode", "code": "D004219", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.429" } } }, { "@type": "MedicalWebPage", "name": "Los Angeles", "alternateName": "Los Angeles", "url": "https://questionsmedicales.fr/mesh/D015141", "about": { "@type": "MedicalCondition", "name": "Los Angeles", "code": { "@type": "MedicalCode", "code": "D015141", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.565" } } }, { "@type": "MedicalWebPage", "name": "Nouvelle-Orléans", "alternateName": "New Orleans", "url": "https://questionsmedicales.fr/mesh/D055820", "about": { "@type": "MedicalCondition", "name": "Nouvelle-Orléans", "code": { "@type": "MedicalCode", "code": "D055820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.697" } } }, { "@type": "MedicalWebPage", "name": "New York (ville)", "alternateName": "New York City", "url": "https://questionsmedicales.fr/mesh/D009519", "about": { "@type": "MedicalCondition", "name": "New York (ville)", "code": { "@type": "MedicalCode", "code": "D009519", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.741" } } }, { "@type": "MedicalWebPage", "name": "Philadelphie", "alternateName": "Philadelphia", "url": "https://questionsmedicales.fr/mesh/D015143", "about": { "@type": "MedicalCondition", "name": "Philadelphie", "code": { "@type": "MedicalCode", "code": "D015143", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.820" } } }, { "@type": "MedicalWebPage", "name": "San Francisco", "alternateName": "San Francisco", "url": "https://questionsmedicales.fr/mesh/D012495", "about": { "@type": "MedicalCondition", "name": "San Francisco", "code": { "@type": "MedicalCode", "code": "D012495", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.875" } } }, { "@type": "MedicalWebPage", "name": "Séoul", "alternateName": "Seoul", "url": "https://questionsmedicales.fr/mesh/D066106", "about": { "@type": "MedicalCondition", "name": "Séoul", "code": { "@type": "MedicalCode", "code": "D066106", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.887" } } }, { "@type": "MedicalWebPage", "name": "Tokyo", "alternateName": "Tokyo", "url": "https://questionsmedicales.fr/mesh/D014041", "about": { "@type": "MedicalCondition", "name": "Tokyo", "code": { "@type": "MedicalCode", "code": "D014041", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Villes", "alternateName": "Cities", "code": { "@type": "MedicalCode", "code": "D002947", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Divya Seth", "url": "https://questionsmedicales.fr/author/Divya%20Seth", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor, Pediatric Specialty Building, Detroit, MI 48201, USA. Electronic address: dseth@dmc.org." } }, { "@type": "Person", "name": "Shweta Saini", "url": "https://questionsmedicales.fr/author/Shweta%20Saini", "affiliation": { "@type": "Organization", "name": "Division of Hospital Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Pavadee Poowuttikul", "url": "https://questionsmedicales.fr/author/Pavadee%20Poowuttikul", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Marc Barthelemy", "url": "https://questionsmedicales.fr/author/Marc%20Barthelemy", "affiliation": { "@type": "Organization", "name": "Université Paris-Saclay, CEA, CNRS, Institut de Physique Théorique, 91191 Gif-sur-Yvette, France." } }, { "@type": "Person", "name": "Sasha Khomenko", "url": "https://questionsmedicales.fr/author/Sasha%20Khomenko", "affiliation": { "@type": "Organization", "name": "Institute for Global Health, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Using high-density perimetry to explore new approaches for characterizing visual field defects.", "datePublished": "2023-06-06", "url": "https://questionsmedicales.fr/article/37285782", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.visres.2023.108259" } }, { "@type": "ScholarlyArticle", "name": "Race and Ethnicity Differences in Disease Severity and Visual Field Progression Among Glaucoma Patients.", "datePublished": "2022-05-30", "url": "https://questionsmedicales.fr/article/35654121", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.05.023" } }, { "@type": "ScholarlyArticle", "name": "Comparing Static Perimetry Protocols of Central Field Testing among Patients with Glaucoma.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37129640", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/OPX.0000000000002020" } }, { "@type": "ScholarlyArticle", "name": "Deep learning approaches to predict 10-2 visual field from wide-field swept-source optical coherence tomography en face images in glaucoma.", "datePublished": "2022-12-05", "url": "https://questionsmedicales.fr/article/36471039", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-25660-x" } }, { "@type": "ScholarlyArticle", "name": "Association of macular vessel density and ganglion cell complex thickness with central visual field progression in glaucoma.", "datePublished": "2023-11-22", "url": "https://questionsmedicales.fr/article/36150750", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2022-321870" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Villes", "item": "https://questionsmedicales.fr/mesh/D002947" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Villes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Villes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Villes", "description": "Comment évaluer l'impact de la pollution urbaine sur la santé ?\nQuels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?\nComment identifier les zones à risque sanitaire en ville ?\nQuels indicateurs de santé sont pertinents en milieu urbain ?\nComment évaluer l'accès aux soins en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Villes", "description": "Quels symptômes sont liés à la pollution de l'air ?\nComment la vie urbaine affecte-t-elle la santé mentale ?\nQuels symptômes sont associés à la chaleur urbaine ?\nQuels signes indiquent une mauvaise qualité de l'eau en ville ?\nQuels symptômes sont liés à l'isolement social en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Villes", "description": "Comment prévenir les maladies liées à la pollution en ville ?\nQuelles mesures peuvent réduire le stress urbain ?\nComment améliorer la qualité de l'eau en milieu urbain ?\nQuelles stratégies aident à prévenir les coups de chaleur ?\nComment favoriser la santé mentale en milieu urbain ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Villes", "description": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?\nComment traiter les effets de la chaleur extrême en ville ?\nQuels traitements sont disponibles pour le stress urbain ?\nComment traiter les maladies liées à l'eau contaminée ?\nQuels traitements sont recommandés pour l'anxiété urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Villes", "description": "Quelles complications peuvent survenir à cause de la pollution ?\nQuels risques de santé sont liés à l'isolement social ?\nQuelles complications peuvent résulter de la chaleur extrême ?\nComment la qualité de l'eau affecte-t-elle la santé ?\nQuelles complications sont liées à la vie urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Villes", "description": "Quels facteurs de risque sont associés à la pollution urbaine ?\nComment le stress urbain influence-t-il la santé ?\nQuels sont les risques liés à la chaleur en milieu urbain ?\nQuels facteurs augmentent le risque de maladies infectieuses en ville ?\nQuels comportements augmentent le risque de problèmes de santé en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=6#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact de la pollution urbaine sur la santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des études épidémiologiques et des indicateurs de santé." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire, des examens cliniques et des enquêtes de santé sont utilisés." } }, { "@type": "Question", "name": "Comment identifier les zones à risque sanitaire en ville ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse géospatiale et les données de santé publique aident à identifier ces zones." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont pertinents en milieu urbain ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de maladies respiratoires, cardiovasculaires et d'obésité sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment évaluer l'accès aux soins en ville ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'accès se mesure par la distance aux établissements de santé et la disponibilité des services." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la pollution de l'air ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux, essoufflement, irritation des yeux et fatigue." } }, { "@type": "Question", "name": "Comment la vie urbaine affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'anxiété et la dépression sont souvent exacerbés par la vie urbaine." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la chaleur urbaine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent déshydratation, épuisement et coups de chaleur." } }, { "@type": "Question", "name": "Quels signes indiquent une mauvaise qualité de l'eau en ville ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent des maladies gastro-intestinales et des éruptions cutanées." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'isolement social en ville ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des symptômes de dépression et d'anxiété." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à la pollution en ville ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques de réduction de la pollution et des campagnes de sensibilisation sont essentielles." } }, { "@type": "Question", "name": "Quelles mesures peuvent réduire le stress urbain ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des espaces verts et des activités communautaires aide à réduire le stress." } }, { "@type": "Question", "name": "Comment améliorer la qualité de l'eau en milieu urbain ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de filtration et des contrôles réguliers de la qualité de l'eau sont nécessaires." } }, { "@type": "Question", "name": "Quelles stratégies aident à prévenir les coups de chaleur ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Éduquer sur l'hydratation et l'ombre, et créer des refuges frais sont des stratégies clés." } }, { "@type": "Question", "name": "Comment favoriser la santé mentale en milieu urbain ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Encourager le soutien social et l'accès à des services de santé mentale est crucial." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les bronchodilatateurs, corticostéroïdes et thérapies respiratoires sont courants." } }, { "@type": "Question", "name": "Comment traiter les effets de la chaleur extrême en ville ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, le repos et, si nécessaire, des soins médicaux." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le stress urbain ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie cognitivo-comportementale et les médicaments peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Comment traiter les maladies liées à l'eau contaminée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, des antibiotiques et des soins symptomatiques." } }, { "@type": "Question", "name": "Quels traitements sont recommandés pour l'anxiété urbaine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies psychologiques et les médicaments anxiolytiques sont souvent prescrits." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir à cause de la pollution ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies respiratoires chroniques et des cancers." } }, { "@type": "Question", "name": "Quels risques de santé sont liés à l'isolement social ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des maladies cardiovasculaires et des troubles mentaux." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de la chaleur extrême ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des coups de chaleur, des déshydratations sévères et des décès." } }, { "@type": "Question", "name": "Comment la qualité de l'eau affecte-t-elle la santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise qualité de l'eau peut entraîner des infections et des maladies gastro-intestinales." } }, { "@type": "Question", "name": "Quelles complications sont liées à la vie urbaine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anxiété, la dépression et des maladies chroniques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à la pollution urbaine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'industrialisation, le trafic routier et l'urbanisation rapide." } }, { "@type": "Question", "name": "Comment le stress urbain influence-t-il la santé ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver des conditions comme l'hypertension et l'anxiété." } }, { "@type": "Question", "name": "Quels sont les risques liés à la chaleur en milieu urbain ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des maladies chroniques sont particulièrement à risque." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies infectieuses en ville ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "La densité de population et l'accès limité à l'eau potable augmentent les risques." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque de problèmes de santé en ville ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, la sédentarité et une alimentation déséquilibrée sont des comportements à risque." } } ] } ] }

Sources (10000 au total)

Race and Ethnicity Differences in Disease Severity and Visual Field Progression Among Glaucoma Patients.

Investigate associations of race/ethnicity and preferred language with baseline glaucoma severity, VF test frequency and disease progression.... Retrospective cohort study.... Patients receiving VF testing at a tertiary eyecare center between 1998 and 2020 with self-identified race, ethnicity and preferred language were included. Outcome measures were VF MD and age at first... Among 29,891 patients with VF measurements between 1998 and 2020, 55.1% were female, 71.0% self-identified as White/Caucasian, 14.0% as Black/African American, 7.4% as Asian and 6.4% as Hispanic, and ... Black, Asian and Hispanic patients had greater baseline severity vs. Whites. Unlike other groups, Black patients had a lower VF frequency vs. Whites and greater VF progression. Disparities in baseline...

Comparing Static Perimetry Protocols of Central Field Testing among Patients with Glaucoma.

On comparing the Humphrey Field Analyzer (HFA) 24-2C Faster, which tests 10 additional points in the central field, with the 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard for detecti... This study aimed to compare the HFA 24-2C Faster with the 24-2 SITA Standard and 10-2 among patients with glaucoma for the number of defective central points, global indices, and testing time.... Sixty eyes of 60 patients with glaucoma and glaucomatous visual field defects on the 24-2 SITA Standard algorithm underwent the 24-2C Faster and 10-2 field tests. The number of central points detected... The 24-2C Faster, on average, detected 5.5 defective points more on the total deviation plot and 2 defective points more on the pattern deviation plot than the 24-2 SITA Standard in central 10°. The 1... Our study demonstrates that the HFA 24-2C Faster may be used for the initial evaluation of the visual field in glaucoma with the added advantage of a shorter testing time compared with the 24-2 SITA S...

Association of macular vessel density and ganglion cell complex thickness with central visual field progression in glaucoma.

To evaluate the association of macular vessel density (VD) and ganglion cell complex (GCC) thickness with 10-2 central visual field (CVF) progression in glaucoma.... In this retrospective cohort study, patients with glaucoma from Diagnostic Innovation in Glaucoma Study with≥five 10-2 visual field (VF) tests and 3-year follow-up before optical coherence tomography ... From 238 eyes (141 patients), 25 eyes (11%) of 16 patients were CVF progressors. In the multivariable analysis of the association between OCT/OCTA parameters and past rate of 10-2 CVF worsening, lower... Lower macular VD and GCC were associated with faster worsening of CVF, and lower macular VD was associated with increased odds of CVF progression. Assessment of macular OCT and OCTA may help detect gl...

Survey on electronic visual field data transfer practices among Japan Glaucoma Society board members.

Visual field (VF) testing in combination with a specialized VF analysis software is critical for characterizing and monitoring visual loss in glaucoma. Although performing glaucoma progression analysi... An internet survey of daily practice patterns regarding electronic VF data transfer at the time of glaucoma referrals (referring/referred) was sent to all 50 JGS board members. The survey consisted wi... The respondents included 33 university hospital ophthalmologists (66%) (Q1), and those scattered throughout Japan (Q2). All respondents used Humphrey Visual Filed Analyzer (HFA) (Q3) and at least one ... An internet survey showed that 80% of the JGS board members were not actively transferring VF data mainly because of the absence of a system in place at institutions for sending and receiving data, al...

Driving and exceptional cases: Supporting relicensing evaluation in patients whose visual fields fail to meet standards.

The UK Driver and Vehicle Licensing Agency's (DVLA) visual field criteria mean that homonymous defects close to fixation are not usually acceptable for driving. Here, we illustrate cases where patient... Clinical assessment of two patients with homonymous loss: a 62-year-old man (PWT) with a dense left upper homonymous quadrantanopia secondary to a right occipital lobe stroke and a 48-year-old woman (... PWT's Esterman test showed a significant central defect failing to meet the standard. His subsequent ophthalmic examination was otherwise unremarkable with excellent visual functions. Clinical evidenc... Conventional visual field tests are not necessarily predictive of real-world driving performance, with drivers' adaptive strategies not being accommodated. In the UK, individuals with visual field los...

The Association Between Regional Macula Vessel Density and Central Visual Field Damage in Advanced Glaucoma Eyes.

Both macular superficial vessel density and ganglion cell complex (GCC) thickness measurement are significantly associated with regional and global 10-degree central visual field (VF) sensitivity in a... The purpose of this study was to evaluate the regional and global structure-function relationships between macular vessel density (MVD) assessed by optical coherence tomography angiography (OCTA) and ... Macular OCTA and 10-2 VF sensitivity of 44 patients [mean deviation (MD) <-10 dB] were evaluated. Regional and global VF mean sensitivity (MS) was calculated from total deviation plots. Superficial an... Lower MS was significantly associated with a reduction in superficial MVD and GCC in each region of both scan sizes for both maps. Associations were weaker in the individual sectors of the whole image... Given a stronger MVD-central 10-degree VF association compared with GCC, as well as stronger GCC-central 5-degree VF association compared with MVD, MVD and GCC are complementary measurements in eyes w...

Prediction of visual field defects from macular optical coherence tomography in glaucoma using cluster analysis.

To assess the accuracy of cluster analysis-based models in predicting visual field (VF) defects from macular ganglion cell-inner plexiform layer (GCIPL) measurements in glaucomatous and healthy cohort... GCIPL measurements were extracted from posterior pole optical coherence tomography (OCT), from locations corresponding to central VF test grids. Models incorporating cluster analysis methods and corre... Clustered models demonstrated globally low sensitivity, but high specificity in the glaucoma cohort (0.28-0.53 and 0.77-0.91, respectively), and high specificity in the healthy cohort (0.91-0.98). Clu... Cluster analysis-based models incorporating age correction and holistic consideration of fovea to optic disc tilt demonstrated superior performance in predicting VF results to pointwise methods in bot...

Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data.

To examine the association between multiple deprivation with late diagnosis and rapid worsening of glaucoma in patients in English hospital eye services (HES).... 602,439 visual fields (VFs) were extracted from five regionally different glaucoma clinics in England. Mean Deviation (MD) worse than -12 dB was used as a surrogate definition for advanced VF loss at ... There was an association between IMD and advanced VF loss at diagnosis in 44,956 patients with 18% (293/1608) and 11% (771/6929) in the most and least deprived IMD decile, respectively. Age-corrected ... Large-scale VF data from clinics indicates that glaucoma severity at presentation to English HES is associated with levels of multiple deprivation. We found no evidence to suggest likelihood of having...